Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.
Name:
OTT-142087-impact-of-prior-the ...
Size:
1.986Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
Buzzoni, RCarnaghi, C
Strosberg, J
Fazio, N
Singh, S
Herbst, F
Ridolfi, A
Pavel, M
Wolin, E
Valle, Juan W
Oh, D
Yao, J
Pommier, R
Affiliation
IRCCS Foundation, National Institute of Tumors, Milan, ItalyIssue Date
2017
Metadata
Show full item recordAbstract
Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P<0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity.Citation
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. 2017, 10:5013-5030 Onco Targets TherJournal
OncoTargets and TherapyDOI
10.2147/OTT.S142087PubMed ID
29081664Type
ArticleLanguage
enISSN
1178-6930ae974a485f413a2113503eed53cd6c53
10.2147/OTT.S142087
Scopus Count
Collections
Related articles
- Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
- Authors: Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC
- Issue date: 2018 Jan
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
- Authors: Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME, RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
- Issue date: 2016 Mar 5
- Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
- Authors: Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC
- Issue date: 2015
- Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
- Authors: Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME
- Issue date: 2015 Dec
- Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.
- Authors: Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N, RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group
- Issue date: 2018